富马酸丙酚替诺福韦在慢乙肝患者中的应用
Application of Tenofovir Alafenamide Fumarate in Patients with Chronic Hepatitis B
DOI: 10.12677/ACM.2024.142497, PDF,   
作者: 刘 雪：山东大学医学融合与实践中心，山东 济南；蒋雪梅*：山东省公共卫生临床中心，山东 济南
关键词: 慢性乙型病毒性肝炎；富马酸丙酚替诺福韦；富马酸替诺福韦二吡呋酯；Chronic Hepatitis B； Tenofovir Alafenamide Fumarate； Tenofovir Disoproxil Fumarate
摘要: 乙型肝炎病毒(Hepatitis B virus, HBV)的慢性持续感染是慢性乙型肝炎(Chronic hepatitis B, CHB)、肝硬化和肝癌发生发展的重要原因，是世界范围内的一个主要公共卫生问题。目前尚缺乏有效清除病毒的药物，用于一线治疗的药物为核苷(核苷酸)类似物(NUC)及干扰素(IFN)。其中富马酸丙酚替诺福韦片(tenofovir alafenamide tablets，TAF，商品名：Vemlidy)，是2018年年底在我国上市的慢乙肝治疗药物，其三期临床研究显示与富马酸替诺福韦二吡呋酯(tenofovir disoproxil fumarate, TDF)相比具有同等的抗病毒效应，更高的肾脏及骨骼安全性更好的肝脏靶向性等优势。本文介绍了该药在真实世界中应用的疗效及安全性。得出了该药无论是对于初治患者还是经治患者，与TDF具有相当的病毒抑制作用，且具有更好的ALT复常率、更好的骨肾安全性，并且对于低病毒血症的患者，换用TAF也能获得更好的完全病毒学应答率。
Abstract: Chronic persistent infection with Hepatitis B virus (HBV) is an important cause of the development of chronic hepatitis B (CHB), cirrhosis, and liver cancer, and it is a major public health problem worldwide. At present, there is no effective drug to clear the virus, and the drugs used for first-line treatment are nucleos(t)ide analogues (NUC) and interferon (IFN). Among them tenofovir alafenamide tablets (TAF, trade name: Vemlidy) is launched in China at the end of 2018, and its phase 3 clinical study showed that it has the same antiviral effect as tenofovir disoproxil fumarate (TDF). Higher kidney and bone safety, better liver targeting and other advantages. This article introduces the efficacy and safety of this drug in the real world. It is concluded that the drug has comparable viral inhibition with TDF in both initial and treated patients, and has better ALT normalization rate, better bone-kidney safety, and better complete virological response rate for patients with low viremia.
文章引用：刘雪, 蒋雪梅. 富马酸丙酚替诺福韦在慢乙肝患者中的应用[J]. 临床医学进展, 2024, 14(2): 3550-3559. https://doi.org/10.12677/ACM.2024.142497

参考文献

[1] Luo, Z., Li, L. and Ruan, B. (2012) Impact of the Implementation of a Vaccination Strategy on Hepatitis B Virus In-fections in China over a 20-Year Period. International Journal of Infectious Diseases, 16, E82-E88. [Google Scholar] [CrossRef] [PubMed]
[2] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版) [J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. [Google Scholar] [CrossRef] 
[3] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版) [J]. 中华传染病杂志, 2023, 41(1): 3-28. [Google Scholar] [CrossRef] 
[4] Buti, M., Gane, E., Seto, W.K., et al. (2016) Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate for the Treatment of Patients with HBeAg-Negative Chronic Hepatitis B Virus Infection: A Randomised, Double-Blind, Phase 3, Non-Inferiority Trial. The Lancet Gas-troenterology & Hepatology, 1, 196-206. [Google Scholar] [CrossRef] 
[5] Chan, H.L., Fung, S., Seto, W.K., et al. (2016) Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate for the Treatment of HBeAg-Positive Chronic Hepatitis B Virus Infection: A Randomised, Double-Blind, Phase 3, Non-Infe- riority Trial. The Lancet Gastroenterology and Hepatology, 1, 185-195. [Google Scholar] [CrossRef] 
[6] Kaneko, S., Kurosaki, M., Tamaki, N., et al. (2019) Tenofovir Alafenamide for Hepatitis B Virus Infection Including Switching Therapy from Tenofovir Disoproxil Fumarate. Journal of Gastroenterology and Hepatology, 34, 2004-2010. [Google Scholar] [CrossRef] [PubMed]
[7] Lim, J., Choi, W.M., Shim, J.H., et al. (2022) Efficacy and Safety of Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate in Treatment-Naïve Chronic Hepatitis B. Liver Interna-tional, 42, 1517-1527. [Google Scholar] [CrossRef] [PubMed]
[8] Jeong, S., Shin, H.P. and Kim, H.I. (2022) Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B. Intervirology, 65, 94-103. [Google Scholar] [CrossRef] [PubMed]
[9] 武媞, 黄康, 赵智蓉, 等. ALT升高、低病毒载量慢性乙型肝炎患者不确定期采用不同抗病毒治疗方案的疗效及安全性[J]. 昆明医科大学学报, 2023, 44(1): 97-103.
[10] Byun, K.S., Choi, J., Kim, J.H., et al. (2022) Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching from Tenofovir Disoproxil Fumarate. Clinical Gastro-enterology and Hepatology, 20, 427-437.e5. [Google Scholar] [CrossRef] [PubMed]
[11] Toyoda, H., Leong, J., Landis, C., et al. (2021) Treatment and Renal Outcomes up to 96 Weeks after Tenofovir Alafenamide Switch from Tenofovir Disoproxil Fumarate in Routine Practice. Hepatology, 74, 656-666. [Google Scholar] [CrossRef] [PubMed]
[12] Nguyen, M.H., Atsukawa, M., Ishikawa, T., et al. (2021) Outcomes of Sequential Therapy with Tenofovir Alafenamide after Long-Term Entecavir. American Journal of Gastroenterology, 116, 1264-1273. [Google Scholar] [CrossRef] [PubMed]
[13] Ogawa, E., Nakamuta, M., Koyanagi, T., et al. (2022) Switching to Tenofovir Alafenamide for Nucleos(T)Ide Analogue-Experienced Patients with Chronic Hepatitis B: Week 144 Results from a Real-World, Multi-Centre Cohort Study. Alimentary Pharmacology & Therapeutics, 56, 713-722. [Google Scholar] [CrossRef] [PubMed]
[14] Kumada, T., Toyoda, H., Tada, T., et al. (2021) Comparison of the Impact of Tenofovir Alafenamide and Entecavir on Declines of Hepatitis B Surface Antigen Levels. European Journal of Gastroenterology & Hepatology, 32, 255-260. [Google Scholar] [CrossRef] 
[15] Uchida, Y., Nakao, M., Tsuji, S., et al. (2020) Significance of Switching of the Nucleos(T)Ide Analog Used to Treat Japanese Patients with Chronic Hepatitis B Virus Infection from Entecavir to Tenofovir Alafenamide Fumarate. Journal of Medical Virology, 92, 329-338. [Google Scholar] [CrossRef] [PubMed]
[16] 秦建增, 张玉华, 杜世奇. 慢性乙型肝炎实施富马酸丙酚替诺福韦治疗的效果与安全性分析[J]. 临床研究, 2021, 29(7): 85-87.
[17] Wong, W.W.L., Pechivanoglou, P., Wong, J., et al. (2019) Antiviral Treatment for Treatment-Naïve Chronic Hepatitis B: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Systematic Reviews, 8, Article No. 207. [Google Scholar] [CrossRef] [PubMed]
[18] Wang, F.D., Zhou, J., Zhang, D.M., et al. (2022) A Study of the Effectiveness of Nucleos(T)Ide Analogues in the Treatment of HBeAg-Positive Chronic Hepatitis B with Normal Ala-nine Aminotransferase and High Level of HBV DNA. Chinese Journal of Hepatology, 30, 389-394.
[19] 程海林, 胡旭东, 夏冰, 等. 富马酸丙酚替诺福韦对恩替卡韦经治后低病毒载量的慢性乙型肝炎患者的临床疗效[J]. 临床肝胆病杂志, 2022, 38(3): 537-540. [Google Scholar] [CrossRef] 
[20] 赵智蓉, 李海雯, 陆霓虹, 等.丙酚替诺福韦治疗慢性乙型肝炎的临床疗效[J]. 昆明医科大学学报, 2021, 42(1): 89-93. [Google Scholar] [CrossRef] 
[21] Chon, H.Y., Ahn, S.H., Kim, Y.J., et al. (2021) Effi-cacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Treatment-Naive Hepatitis B Patients. Hepatology International, 15, 1328-1336. [Google Scholar] [CrossRef] [PubMed]
[22] Sripongpun, P., Kim, W.R., Mannalithara, A., et al. (2022) Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients with Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 20, 230-232. [Google Scholar] [CrossRef] [PubMed]
[23] Liang, L.Y., Yip, T.C., Lai, J.C., et al. (2022) Tenofovir Alafenamide Is Associated with Improved Alanine Aminotransferase and Renal Safety Compared to Tenofovir Disoproxil Fumarate. Journal of Medical Virology, 94, 4440- 4448. [Google Scholar] [CrossRef] [PubMed]
[24] Li, Z.B., Li, L., Niu, X.X., et al. (2021) Switching from Entecavir to Tenofovir Alafenamide for Chronic Hepatitis B Patients with Low-Level Viraemia. Liver International, 41, 1254-1264. [Google Scholar] [CrossRef] [PubMed]
[25] Wong, G.L., Tse, Y.K., Wong, V.W., et al. (2015) Long-Term Safety of Oral Nucleos(T)Ide Analogs for Patients with Chronic Hepatitis B: A Cohort Study of 53,500 Subjects. Hepatology, 62, 684-693. [Google Scholar] [CrossRef] [PubMed]
[26] Tien, C., Xu, J.J., Chan, L.S., et al. (2015) Long-Term Treatment with Tenofovir in Asian-American Chronic Hepatitis B Patients Is Associated with Abnormal Renal Phosphate Handling. Digestive Diseases and Sciences, 60, 566-572. [Google Scholar] [CrossRef] [PubMed]
[27] Kahraman, R., Şahin, A., Öztürk, O., et al. (2022) Effects of Long-Term Tenofovir and Entecavir Treatment on Bone Mineral Density in Patients with Chronic Hepatitis B. Turkish Journal of Gastroenterology, 33, 35-43. [Google Scholar] [CrossRef] [PubMed]
[28] Wong, G.L., Chan, H.L., Tse, Y.K., et al. (2018) Chronic Kidney Disease Progression in Patients with Chronic Hepatitis B on Tenofovir, Entecavir, or No Treatment. Alimentary Phar-macology & Therapeutics, 48, 984-992. [Google Scholar] [CrossRef] [PubMed]
[29] Scaglione, S.J. and Lok, A.S. (2012) Effectiveness of Hepatitis B Treatment in Clinical Practice. Gastroenterology, 142, 1360-1368.e1. [Google Scholar] [CrossRef] [PubMed]
[30] Scherzer, R., Estrella, M., Li, Y., et al. (2012) Association of Tenofovir Exposure with Kidney Disease Risk in HIV Infection. Aids, 26, 867-875. [Google Scholar] [CrossRef] 
[31] EASL (2017) 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. Journal of Hepatology, 67, 370-398. [Google Scholar] [CrossRef] [PubMed]
[32] Jung, C.Y., Kim, H.W., Ahn, S.H., et al. (2022) Higher Risk of Kidney Function Decline with Entecavir than Tenofovir Alafenamide in Patients with Chronic Hepatitis B. Liver In-ternational, 42, 1017-1026. [Google Scholar] [CrossRef] [PubMed]
[33] Farag, M.S., Fung, S., Tam, E., et al. (2021) Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study. Journal of Viral Hepatitis, 28, 942-950. [Google Scholar] [CrossRef] [PubMed]
[34] Hosaka, T., Suzuki, F., Kobayashi, M., et al. (2022) Renal Safety and Bi-ochemical Changes for 2 Years after Switching to Tenofovir Alafenamide from Long-Term Other Nucleotide Analog Treatment in Patients with Chronic Hepatitis B. Hepatology Research, 52, 153-164. [Google Scholar] [CrossRef] [PubMed]
[35] Fong, T.L., Lee, B.T., Tien, A., et al. (2019) Improvement of Bone Min-eral Density and Markers of Proximal Renal Tubular Function in Chronic Hepatitis B Patients Switched from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide. Journal of Viral Hepatitis, 26, 561-567. [Google Scholar] [CrossRef] [PubMed]
[36] Lee, B.T., Chang, M., Lim, C., et al. (2021) Bone and Renal Safety Profile at 72 Weeks after Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients. JGH Open: An Open Access Journal of Gastroenterology and Hepatology, 5, 258-263. [Google Scholar] [CrossRef] [PubMed]
[37] Haskelberg, H., Hoy, J.F., Amin, J., et al. (2012) Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLOS ONE, 7, e38377. [Google Scholar] [CrossRef] [PubMed]
[38] Grigsby, I.F., Pham, L., Mansky, L.M., et al. (2010) Tenofovir Treatment of Primary Osteoblasts Alters Gene Expression Profiles: Implications for Bone Mineral Density Loss. Bio-chemical and Biophysical Research Communications, 394, 48-53. [Google Scholar] [CrossRef] [PubMed]
[39] Seto, W.K., Asahina, Y., Brown, T.T., et al. (2018) Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate over 2 Years in Patients with Chronic HBV Infection. Clinical Gastroenterology and Hepatology. [Google Scholar] [CrossRef] [PubMed]
[40] Que, X., Hung, M.Y., Yeang, C., et al. (2018) Oxidized Phospho-lipids Are Proinflammatory and Proatherogenic in Hypercholesterolaemic Mice. Nature, 558, 301-306. [Google Scholar] [CrossRef] [PubMed]
[41] Suzuki, K., Suda, G., Yamamoto, Y., et al. (2021) Tenofovir-Disoproxil-Fumarate Modulates Lipid Metabolism via Hepatic CD36/PPAR-Alpha Activation in Hepatitis B Virus Infection. Journal of Gastroenterology, 56, 168-180. [Google Scholar] [CrossRef] [PubMed]
[42] Suzuki, K., Suda, G., Yamamoto, Y., et al. (2022) Effect of Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide on Lipid Profiles in Patients with Hepatitis B. PLOS ONE, 17, e0261760. [Google Scholar] [CrossRef] [PubMed]
[43] Jeong, J., Shin, J.W., Jung, S.W., et al. (2022) Tenofovir Alafenamide Treatment May Not Worsen the Lipid Profile of Chronic Hepatitis B Patients: A Propensity Score-Matched Analysis. Clinical and Molecular Hepatology, 28, 254-264. [Google Scholar] [CrossRef] [PubMed]
[44] Zhang, Y.Q., Li, Z.P., Luo, Q.M., et al. (2022) Changes in Blood Lipids in Patients with Chronic Hepatitis B after 48 Weeks of Tenofovir Alafenamide Treatment: A Prospective Re-al-World Clinical Study. Antiviral Therapy, 27. [Google Scholar] [CrossRef] 
[45] Yeh, M.L., Liang, P.C., Trinh, S., et al. (2022) Body Weight Changes in Treated Hepatitis B Patients Switching to Tenofovir Alafenamide. Journal of the Formosan Medical Asso-ciation, 121, 1273-1282. [Google Scholar] [CrossRef] [PubMed]
[46] Hige, S., Aoki, K., Nakamoto, D., et al. (2024) Real-World Safety and Effectiveness of Tenofovir Alamenamide for 144 Weeks in Japanese Patients with Chronic Hepatitis B. Journal of Viral Hepatitis. [Google Scholar] [CrossRef] [PubMed]
[47] Liu, Z., Zhao, Z., Ma, X., Liu, S. and Xin, Y. (2023) Renal and Bone Side Effects of Long-Term Use of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide Fumarate in Patients with Hepatitis B: A Network Meta-Analysis. BMC Gastroenterology, 23, Article No. 384. [Google Scholar] [CrossRef] [PubMed]
[48] Ogawa, E., Jun, D.W., Toyoda, H., et al. (2024) Increased Spine Bone Density in Patients with Chronic Hepatitis B Switched to Tenofovir Alafenamide: A Prospective, Multinational Study. Alimentary Pharmacology & Therapeutics, 59, 239-248. [Google Scholar] [CrossRef] [PubMed]

为你推荐